Concord Biotech share up 3% at Rs 1,158 (2026)

Price action: stock trades in the green

Concord Biotech was trading 3.02% higher at Rs 1,158.00 compared with its previous close of Rs 1,124.05. The update places the stock in positive territory during the session, with the last reported time stamp of Fri May 22, 2026 06:31:53. Such moves are often tracked closely by investors when the company has an active calendar of corporate disclosures and investor interactions. The latest trade data also provides a clear reference point for the day’s trading range.

Intraday range reported for the session

The stock was reported to be trading in the price range of Rs 1,159.15 and Rs 1,115.65. That range captures both the session high and low cited in the data. Range metrics can help investors gauge volatility for the day, especially when compared with prior sessions. While the data does not provide volumes, the stated range indicates the stock moved across a relatively wide band before being last seen near Rs 1,158.

Another recent price snapshot in the feed

Separately, the same information set also notes that Concord Biotech’s share price moved down by -3.63% from its previous close of Rs 1,228.90, with the stock last traded at Rs 1,184.40. The specific date for this snapshot is not mentioned in the provided text, so it is best read as an additional market data point included in the feed. Taken together with the May 22, 2026 update, it shows that the stock has seen both upward and downward moves in recent quoted observations.

What Concord Biotech does

Concord Biotech Limited is described as an India-based, research and development-driven biopharma company. The company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The disclosure also notes that Concord Biotech operates across diverse therapeutic segments, although the segment list is not detailed in the provided text.

SEBI LODR disclosures: investor and analyst interactions

The information set includes multiple references to intimations of analyst or institutional investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015. These items include schedules for meetings on 25th February 2026 and 26th February 2026. Another intimation references a meeting scheduled to be held on March 06, 2026. One line also references a schedule to be held on “March…”, but the date is truncated in the provided text.

Such meeting schedules are typically disclosed to keep the market informed about structured interactions with investors and analysts. The feed does not include details such as venue, participant names, or whether these were group meetings or one-on-ones.

Board meeting reference: February 2026 agenda

The feed states that a meeting of the Board of Directors of the company was scheduled on 11/02/2026, inter alia, to consider quarterly results. It also separately notes that a board meeting was held on Feb 11, 2026, with the meeting agenda stated as quarterly results. This kind of board meeting reference is a key corporate governance marker for listed companies, as it aligns with the regular financial reporting calendar.

Earnings calls and results-related communication

The disclosures also reference an earnings call arranged to discuss unaudited standalone and consolidated financial results for the first quarter ended June 30, 2025, scheduled on Monday, 11th August, 2025 at 04:00 P.M. IST. In addition, there is a reference to a board meeting scheduled on 08/08/2025 to consider and approve standalone and consolidated unaudited financial results for the first quarter ended June 30, 2025, along with the limited review report.

Another item in the feed references an earnings call for audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2025, scheduled on Friday, 30th May, 2025 at 02:30 P.M. The text also states that the said earning call was held today at 02:30 PM (IST), without specifying the date of that “today” line.

Shareholder events and dividend history mentioned

The feed notes that the 40th Annual General Meeting was to be held on 9th September, 2025 at 4:00 PM through OAVM. It also mentions an intimation of schedule of an analyst/institutional investor meeting on 19th September, 2025 at 11:00 AM IST.

On dividends, the provided information lists final dividend entries including “Final 1070% 10.7” with ex-dividend date Sep 03, 2025 and announced on May 29, 2025. It also lists “Final 875% 8.75” with ex-dividend date Jun 21, 2024 and announced on May 23, 2024. The feed does not provide additional context such as record dates beyond these fields.

Key facts table: price and corporate events

Registered office and registrar details in the disclosure

The feed includes the company’s registered office address as 1482-1486, Trasad Road, Dholka, Ahmedabad, Gujarat 382225, with telephone number 079-68138700 and email complianceofficer@concordbiotech.com. It also lists the website as http://www.concordbiotech.com.

Registrar details are provided as Link Intime, address C 101, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai 400083, Maharashtra. The registrar phone numbers are 022-49186270 and 49186200, with fax 022-49186060 and email rnt.helpdesk@linkintime.co.in. The registrar website is listed as http://www.linkintime.co.in.

What investors typically track from here

Based on the items present in the disclosure feed, investors tracking Concord Biotech may keep an eye on future board meeting outcomes linked to quarterly results and any follow-up investor meeting schedules under SEBI LODR. In the near term, the key factual takeaway in the latest market snapshot is the stock’s move to Rs 1,158.00, up 3.02% from the previous close, alongside the reported intraday range.

Conclusion

Concord Biotech’s latest quoted trade shows the stock up 3.02% at Rs 1,158.00 on May 22, 2026, with a cited range of Rs 1,159.15 to Rs 1,115.65. The accompanying disclosure trail highlights a steady cadence of board and investor-related intimations, including a Feb 11, 2026 board meeting for quarterly results and multiple analyst meeting schedules in Feb and March 2026.